Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division
Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva
Avacta has announced an extension to its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620, ‘Daewoong’). AffyXell Therapeutics, the joint venture established in South Korea by the
Expansion of Partnership with Daewoong Pharmaceutical to Include COVID-19 Neutrali s ing Affimer Therapy
Update on COVID-19 Rapid Antigen Test Development Partnership with Cytiva
Infectivity assays carried out in collaboration with Glasgow University show that Affimer reagents prevent infection of human cells by a SARS-COV-2 model virus